Johnson & Johnson to Acquire Proteologix, Inc.

Johnson & Johnson to Acquire Ambrx Biopharma in ~$2 Billion All-Cash Deal

January 8, 2024

Pharmaceuticals

Johnson & Johnson announced it has entered into a definitive agreement to acquire Ambrx Biopharma in an all-cash merger transaction valued at about $2 billion (about $1.9 billion net of estimated cash acquired). The deal is intended to add Ambrx’s proprietary synthetic biology and ADC (antibody-drug conjugate) technology platform and its clinical and preclinical oncology pipeline to J&J’s targeted oncology therapeutics efforts.

Johnson & Johnson Acquires Yellow Jersey Therapeutics from Numab for $1.25B

May 28, 2024

Biotechnology

Johnson & Johnson agreed to acquire Yellow Jersey Therapeutics, a wholly owned spin-off of Numab Therapeutics, for $1.25 billion in cash to obtain global rights to NM26, a Phase‑2‑ready bispecific antibody for atopic dermatitis. The deal was announced May 28, 2024 (Numab/ Novo Holdings) and completed in July 2024; J&J will develop, manufacture and commercialize NM26 globally.

Eli Lilly Acquires Protomer Technologies

July 14, 2021

Biotechnology

Eli Lilly and Company announced the acquisition of Protomer Technologies, a private biotechnology company based in Pasadena, California, to enhance Lilly's diabetes pipeline. The deal has potential value of over $1 billion contingent on development and commercial milestones; Lilly previously held a 14% stake and is acquiring the remaining shares to gain Protomer's glucose‑sensing insulin programs and protein‑engineering MEPS platform.

Sanofi to Acquire Provention Bio for $2.9 Billion

March 13, 2023

Pharmaceuticals

Sanofi has entered into an agreement to acquire Provention Bio for $25.00 per share in cash, valuing the deal at approximately $2.9 billion. The transaction will be implemented via a cash tender offer followed by a merger, with completion expected in the second quarter of 2023 subject to customary closing conditions.

Johnson & Johnson Acquires Intra-Cellular Therapies

April 2, 2025

Healthcare Services

Johnson & Johnson has acquired Intra-Cellular Therapies, paying $132 per share in cash for all outstanding shares, for an equity value of approximately $14.6 billion. The deal adds CAPLYTA (lumateperone) and a clinical-stage pipeline, including ITI-1284, to strengthen J&J’s neuroscience portfolio.

Merck Acquires Pandion Therapeutics

February 25, 2021

Biotechnology

Merck will acquire Pandion Therapeutics for $60 per share in cash, representing an approximate total equity value of $1.85 billion, via a tender offer and subsequent merger. Pandion is a clinical-stage biotechnology company focused on precision immune modulators (TALON platform) with lead candidate PT101 targeting regulatory T cells for autoimmune diseases; the transaction is expected to close in the first half of 2021 subject to customary conditions.